Matured hiPSC-derived cardiomyocytes possess dematuration plasticity
Human induced Pluripotent Stem Cell-derived cardiomyocytes (hiPSC-CMs) are increasingly used to identify potential factors capable of inducing endogenous cardiomyocyte proliferation to regenerate the injured heart. L-type calcium channel blockers have previously been identified as a class of factors capable of inducing matured hiPSC-CMs to proliferate. However, the mechanism by which L-type calcium channel blockers promote hiPSC-CM proliferation remains unclear. Here we provide evidence that matured hiPSC-CMs possess plasticity to undergo dematuration in response to certain pharmacological compounds. Consistent with primary cardiomyocyte maturation during perinatal development, we found that centrosome disassembly occurs in hiPSC-CMs during plate-based, temporal, maturation. A small molecule screen identified nitrendipine, an L-type calcium channel blocker, and 1-NA-PP1, a Src kinase inhibitor, as factors capable of inducing centrosome reassembly in a subpopulation of hiPSC-CMs. Furthermore, centrosome-positive hiPSC-CMs were more likely to exhibit cell cycle activity than centrosome-negative hiPSC-CMs. In contrast, neither nitrendipine or 1-NA-PP1 induced centrosome reassembly, or cell cycle activity, in neonatal rat ventricular myocytes (NRVMs). Differential bulk transcriptome analysis indicated that matured hiPSC-CMs, but not NRVMs, treated with nitrendipine or 1-NA-PP1 undergo dematuration. ScRNA transcriptome analysis supported that matured hiPSC-CMs treated with either nitrendipine or 1-NA-PP1 undergo dematuration. Collectively, our results indicate that matured hiPSC-CMs, but not primary NRVMs, possess plasticity to undergo dematuration in response to certain pharmacological compounds such as L-type calcium channel blockers and Src-kinase inhibitors. This study shows that once mature, hiPSC-CMs may not maintain their maturity under experimental conditions which may have implications for experimental systems where the state of hiPSC-CM maturation is relevant.
Authors
- Henrik Andersson (ORCID: https://orcid.org/0000-0002-6020-5177)
- Anna Walentinsson
- Daniela Später (ORCID: https://orcid.org/0000-0002-5398-1784)
- Ruofan Wei
- Alejandro Hidalgo (ORCID: https://orcid.org/0000-0002-8395-7179)
- Ellen Poon (ORCID: https://orcid.org/0000-0002-9280-3681)
- Maxwell Kwok (ORCID: https://orcid.org/0000-0001-5920-9341)
- David C. Zebrowski
- Frederik Adam Bjerre (ORCID: https://orcid.org/0000-0001-6733-4599)
- Ditte Caroline Andersen (ORCID: https://orcid.org/0000-0003-4940-7912)
- Yen Chin Hui
- Meng Fang (ORCID: https://orcid.org/0000-0001-6702-5374)
- Qing‐Dong Wang (ORCID: https://orcid.org/0000-0001-9570-4411)
Institutions
- The University of Melbourne (AU)
- Chinese University of Hong Kong (HK)
- University of Southern Denmark (DK)
- Odense University Hospital (DK)
- Karolinska Institutet (SE)
- Integrated Cardio Metabolic Centre (SE)
- Gen-9 (United States) (US)
- AstraZeneca (Sweden) (SE)
- Murdoch Children's Research Institute (AU)
- New York University (US)
Publication Details
- Journal
- Journal of Molecular and Cellular Cardiology Plus
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1016/j.jmccpl.2025.100295
- Citations
- 3
- Primary Topic
- Pluripotent Stem Cells Research
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- AstraZeneca
- Lundbeckfonden
- Novo Nordisk
- Odense Universitetshospital
- Chinese University of Hong Kong
- Novo Nordisk Fonden
- H. Lundbeck A/S
- Health and Medical Research Fund